Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Supernus nets $48.8mm in initial public offering

Executive Summary

Supernus Pharmaceuticals Inc. (CNS diseases) has netted $48.8mm in its initial public offering of 10mm shares at $5. Existing shareholders bought 6mm of the shares. Last month, the company announced terms of 5.8mm shares at $12-14, then increased the number of shares, to 11mm, and lowered the price to $5.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies